Drug Trial Radar · NCT05318976
A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation
Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
207
Actual
Start
Feb 28, 2022
Primary completion
May 12, 2025
Study completion May 12, 2025
Sponsor
- Lead sponsor
- Inmune Bio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this Phase 2 Alzheimer's study is to determine whether 1.0 mg/kg XPro1595 confers a benefit on cognition, function, and biomarkers of white matter and to further evaluate safety and tolerability. The objectives of this study are to determine the safety, tolerability, and efficacy of XPro1595 in patients with early ADi.
Conditions
- Alzheimer Disease
- Dementia
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Tauopathies
- Neurodegenerative Diseases
- Neurocognitive Disorders
- Mental Disorders
- Mild Cognitive Impairment
Interventions
XPro1595Drug
XPro1595 will be delivered by subcutaneous injection once a week
PlaceboDrug
Placebo will be delivered by subcutaneous injection once a week
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Early and Mild Alzheimer's Cognitive Composite (EMACC)Time frame: 24 Weeks
Locations
41 sites in 8 countries. Site status is shown where the registry gives one.
INmune Bio Investigational Site
Darlinghurst, New South Wales, Australia
INmune Bio Investigational Site
Macquarie Park, New South Wales, Australia
INmune Bio Investigational Site
Adelaide, South Australia, Australia
INmune Bio Investigational Site
Box Hill, Victoria, Australia
INmune Bio Investigational Site
Carlton, Victoria, Australia
INmune Bio Investigational Site
Ivanhoe, Victoria, Australia
INmune Bio Investigational Site
Parkville, Victoria, Australia
INmune Bio Investigational Site
Nedlands, Western Australia, Australia
INmune Bio Investigational Site
Kelowna, Canada
INmune Bio Investigational Site
Ottawa, Canada
INmune Bio Investigational Site
Sherbrooke, Canada
INmune Bio Investigational Site
Toronto, Canada
INmune Bio Investigational Site
Toronto, Canada
INmune Bio Investigational Site
West Vancouver, Canada
INmune Bio Investigational Site
Brno, Czechia
INmune Bio Investigational Site
Pilsen, Czechia
INmune Bio Investigational Site
Prague, Czechia
INmune Bio Investigational Site
Prague, Czechia
INmune Bio Investigational Site
Rychnov nad Kněžnou, Czechia
INmune Bio Investigational Site
Bron, France
INmune Bio Investigational Site
Nantes, France
INmune Bio Investigational Site
Toulouse, France
INmune Bio Investigational Site
Berlin, Germany
INmune Bio Investigational Site
Chemnitz, Germany
INmune Bio Investigational Site
Bialystok, Poland
INmune Bio Investigational Site
Bydgoszcz, Poland
INmune Bio Investigational Site
Wroclaw, Poland
INmune Bio Investigational Site
Barcelona, Spain
INmune Bio Investigational Site
Barcelona, Spain
INmune Bio Investigational Site
Córdoba, Spain
INmune Bio Investigational Site
Madrid, Spain
INmune Bio Investigational Site
Seville, Spain
INmune Bio Investigational Site
Valencia, Spain
INmune Bio Investigational Site
Valencia, Spain
INmune Bio Investigational Site
Birmingham, United Kingdom
INmune Bio Investigational Site
Bristol, United Kingdom
INmune Bio Investigational Site
Guildford, United Kingdom
INmune Bio Investigational Site
London, United Kingdom
INmune Bio Investigational Site
Motherwell, United Kingdom
INmune Bio Investigational Site
Plymouth, United Kingdom
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.